



ASX ANNOUNCEMENT

10 FEBRUARY 2025

## **UCHICAGO MEDICINE JOINS CHM CDH17 PHASE 1/2 CLINICAL TRIAL**

- **CHM CDH17 is the world's first anti CDH17-directed CAR-T cell therapy**
- **University of Chicago Medicine is a world leader in developing cancer therapies**
- **The Phase 1 part of this clinical trial aims to recruit up to 15 patients**
- **Three patients have now been dosed, with five successful manufacturing runs**

**Melbourne, Australia, 10 February 2025:** Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), an Australian leader in cell therapy, is pleased to announce that University of Chicago Medicine (UChicago Medicine) is open to enrol patients in the Phase 1/2 multi-centre clinical trial for CHM CDH17 cell therapy.

The Phase 1/2 trial (NCT06055439) is a two-stage study designed to determine a recommended Phase 2 dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumours. CHM CDH17 is a 3rd generation, novel CAR T cell therapy that targets CDH17, a cancer target associated with poor prognosis and metastases in the most common gastrointestinal tumours.

The UChicago Medicine site will be lead by Associate Professor Dan Olson, his research is focused on developing new immunotherapy treatments for solid tumours including CAR-T cell therapy. UChicago Medicine is also home to Professor Michael Bishop, a member of Chimeric's Scientific Advisory Board, who is renowned for pioneering stem cell transplantation and discovering breakthrough cancer treatments.

"We are gaining momentum on the CHM CDH17 study and are delighted to welcome UChicago Medicine to the trial," said Dr Rebecca McQualter, Chimeric Therapeutics' Chief Executive Officer.

"Following five successful manufacturing runs of CHM CDH17, we've now seen three patients dosed across the Sarah Cannon and UPenn sites and look forward to bringing announcing further updates on progress as soon as we're able."

The Phase 1 portion of this study is expected to enrol 15 patients and lead to dose selection and expansion with indication-specific Phase 2 cohorts.



## **ABOUT CHIMERIC THERAPEUTICS**

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 4 clinical stage programs.

CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr. Xianxin Hua, professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR T was published by Dr. Hua and his colleagues in 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CLTX is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CLTX CAR T is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated. From the CORE-NK platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

*Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.*

### **Contact**

Investors

Dr Rebecca McQualter

Chief Executive Officer

Chimeric Therapeutics

E: [investors@chimerictherapeutics.com](mailto:investors@chimerictherapeutics.com)

W: [www.chimerictherapeutics.com](http://www.chimerictherapeutics.com)

Media

Matthew Wright

NWR Communications

T: +61 451 896 420

E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)